lmmunoassays with a monoclonal antibody (A-i ) detect a prevalent dimorphism in plasma coagulation factor IX. The
were as previously reported.28 Immunassays.
Factor IX antigen was determined using immunoradiometric assays. The A-I antibody or the A-S antibody (antiheavy chain of factor IXa) were used to coat microtiter plates and bind factor IX samples. Bound factor IX was quantitated with radioiodinated A-7 antibody (anti-light chain of factor IXa).'7 In some experiments, the labeled antibody was a fractionated polyclonal preparation.29 Another monocbonal antibody to an epitope in the heavy chain of IXa #{176} could be substituted for solid-phase A-S.
Immunoreactive activation peptide and factor IX were also tested in an antibody binding inhibition assay. Serial twofold dilutions of factor IX or test samples in 0.15 mol/L NaC1/0.02 mol/L Tris-HC1 (pH 7.2), with 1 mg/mL ovalbumin were mixed with peroxidase conjugated3'
A-l antibody for 2 hours at room temperature. The mixture of radioiodinated antibody (100 zL) and antigen was then added in triplicate to microtiter wells previously coated with factor Ix at a concentration of 1 g/mL. After 2 hours at 37#{176}C, bound antibody was quantitated with addition of peroxidase substrate (o-pheynlenediamine in 0.1 mol/L sodium citrate, pH 4.5). Reaction offactor IXfusion proteins with monoclonal antibody A-I . The 17 expression system described by Studier and Moffat'2 was used for expression of the different fragments of human factor IX cDNA.'4 The fusion proteins were produced as insoluble proteins in Escherichia coli and were rendered soluble by boiling in a buffer containing SDS and 2-mercaptoethanol. An aliquot of each solubilized protein was applied to Laemmli" gels with 4% acrylamide in stacking gels and 10% acrylamide in running gels for electrophoresis. The electrophoretically fractionated proteins were transferred to a nitrocellubose membrane and reacted with either '251-A-1 or with nonradioactive A-l antibody followed by '251-protein A (ICN, Cleveland).
As previously described,'4 a A gtl 1 expression library was constructed containing random, small DNase I fragments of the coding region of a human factor IX cDNA.
The recombinant phage were screened for immunoreactivity, using A-I monocbonal antibody and '25I-Protein A or '25I-A-1 prepared by chloramine-T technique.'7 Ten-milliliter aliquots of the purified recombinant phage were grown from the pure phage stocks, the DNA was isolated," and the EcoRI fragment containing factor IX cDNA was ligated direly into the single-strand phage M13 mpl8 for dideoxy sequencing using 35-S dATP.'7
Immunoblotting offactors IX and IXa with A-i . Two-to 5-ag samples of factor IX or factor IXa were applied to lanes of Laemmli gels and electrophoresed prior to transfer to nitrocellulose. After nonspecific binding was blocked by soaking the nitrocellulose in 5% nonfat dry milk in 0. 15 mol/L NaC1/0.02 mol/L Tris-HC1 (pH 7.2) with 0.2% sodium azide, radioiodinated monocbonal antibodies with a specific activity of 2 Ci/ ig were diluted to 106 cpm/mL in the same solution for reaction with nitrocellulose for 2 hours at room temperature. Nitrocellulose sheets were washed in buffer without 5% milk solids three times and then exposed overnight for radioautography.
Studies 2) . These peptides did not inhibit the binding of other monoclonal antibodies to immobilized factor IX (data not shown).
The peak with the greatest retention time on reverse-phase HPLC (peptide III, Fig IA; Fig lB, gels 2 and 3) The gel profiles for the first and second peaks (I and II) were identical and are shown in gel 1 . The third peak (Ill) is shown in gels 2 and 3. Samples of 50 sg of peak II (gel 1 ) without mercaptoethanol and 30 g of peak Ill with 5% mercaptoethanol (gel 2) and 1 including residue 148 with the polymorphism (Fig 4) . The
For personal use only. A-7) . The radio iodinated antibody in the two antibody assays is indicated by an asterisk. All four nonaffected males who were children of the four heterozygous carriers had the Ala allele (IV-6, IV-7, IV-iO, IV-i 1). The carrier status of seven possible carriers could be predicted in generation IV by the immunoassay result.
Four tested as noncarriers (IV-5, IV-9, IV-i6, IV-i7), and three were predicted to be carriers (IV-l3, IV-14, IV-i5) ( Table  3 , Fig 5) .
Carrier testing was confirmed by restriction fragment length polymorphisms. Leukocyte DNA was obtained from two patients (IV-8 and IV-i2) and five other family members (111-5, 111-7, and III-7a and IV-13, IV-i4). DNA was digested with TaqI and hybridyzed to a cDNA probe. The For personal use only. on November 10, 2017. by guest www.bloodjournal.org From Family study with A-i (Thr/Ala).
Immunoassay alleles (T. Thr; A. Ala) are shown for the family members tested ( 
